(PHILADELPHIA) — As the world’s leading
professional organization representing physicians who treat people
with cancer, the American Society
of Clinical Oncology (ASCO) and
many of its 25,000+ members meet this
weekend in Chicago at of the largest annual medical conferences
in the world. Physicians from the Abramson
Cancer Center of the University of Pennsylvania – like the rest of their
ASCO colleagues – are
committed to advancing the education of oncologists and other oncology
professionals, to advocating for policies that provide access to
high-quality cancer care, and to supporting the clinical trials
system and the need for increased clinical and translational research.
Starting tomorrow, reporters can find in-depth, up-to-the-minute
coverage of sessions and presentations from the annual ASCO meeting
at OncoLink, the
Abramson Cancer Center’s award-winning cancer resource
website.
Friday, June 1st
1-4 p.m. |
Integrating Imaging Tools for Cancer Screening
and Patient Management
Should routine breast cancer staging include MRI?
Speaker/Education Book Manuscript Presentation:
Mitchell D. Schnall, MD, PhD
The Biology of Treagtment of HER2-Postitive Breast Cancer: the
Old and the New
“Where did it all begin?”
Speaker/Education Book Manuscript:
Mark I. Greene, MD
|
Saturday, June 2nd
7:30 – 10:30
a.m. |
Melanoma – Oral Presentations
Co-Chair:
Lynn M Schuchter, MD
Discussion Leader:
Keith T. Flaherty, MD
|
8 a.m. – 12
p.m. |
Lymphoma and Plasma Cell Disorders – General
Poster Session
Poster No: U7 Abstract
No. 8057
A two-arm prospective trial evaluating the ability of
EBC iPCR to diagnose and monitor post-transplant lymphoproliferative
disorder.
Presenter:
Donald E. Tsai, MD, PhD
|
Sunday, June 3rd
8 a.m. – 12
p.m. |
Tumor Biology and Human Genetics
General Poster Session
Poster No: HH3 Abstract
No. 10549
Pathologic predictors of BRCA1/BRCA2 (B!/B@) mutations in African-American
women with early-onset breast cancer
Presenter:
Susan M. Domcheck, MD
|
| 9:15 – 10:30
a.m. |
Time Management: Balancing Career and Family
Life
Fellow Educators Session
Chair:
Lynn M. Schuchter, MD
|
| 11 a.m. – 12:15 p.m. |
When is a Molecular Test Ready for Routine
Clinical Practice? - Presentation
How Should We Use Molecular Tests for Breast Cancer
Treatment Decisions?
Speaker/Chair:
Angela DeMichele, MD
|
Sunday, June 3rd
1:15 -2:30 p.m. |
Writing an Outstanding Scientific Manuscript – An
Insider’s View from the Editor’s of the Journal
of Clinical Oncology & Cell
Fellow Educators Session
Speaker/Chair:
Daniel G. Haller, MD
|
| 2 – 6 p.m. |
Genitouirinary CAncer
General Poster Session
Poster No: F5 Abstract
No. 5116
Prevalence of osteoporosis and osteopenia during androgen deprevation (ADT)
for prostate cancer: Baseline data from a large randomized controlled
trial
Presenter:
S. Bruce Malkowicz, MD
|
Monday, June 4th
7:30 –8:45 a.m. |
Evidence of Therapeutic Effectiveness: How
much is Enough to Change Clinical Practice?
Education Session
Introduction Speaker/Chair:
Susan Ellenberg, PhD
|
| 8 a.m. – 12 p.m. |
Gastrointestinal (Colorectal) Cancer
General Poster Session
Poster No: E7 Abstract
No. 4073
Magnitude of Progression-free survival improvement and treatment
duration in metastatic colorectal cancer for bevacizumab in
combination with oxaliplatin-containing regimens: An analysis
of two phase III studies.
Presenter:
Bruce J. Giantonio, MD
|
| 9 a.m. – 12 p.m. |
Breast Cancer – Local-Regional and
Adjuvant Therapy
Oral Presentation
Discussion Leader:
Lawrence J. Solin, MD, FACR
|
| 11 a.m. – 12 p.m. |
Head and Neck Cancer
Poster Discussion
Poster No: 3 Abstract
No. 6019
Sorafenib targets BRAF and VEGER in metastatic thyroid carcinoma
Presenter:
Vandana Gupta, MD
|
| 11 a.m. – 12:15 p.m. |
What Oncologists Should Know about Hereditary
Gastric, Kidney, and Thyroid Cancers
Education Session
Introduction Speaker/Chair:
Susan M Domchek, MD
Thyroid abnormalities and inherited cancer syndromes
Education Session
Speaker
Kate Nathanson, MD
|
| 5 – 6 p.m. |
Sarcoma
Poster Discussion
Poster No: 5 Abstract
No. 10021
Utility of PET scan in predicting chemotherapeutic response
in soft tissue sarcoma patients
Presenter:
David M. Mintzer, MD
|
###
The Abramson Cancer Center (ACC) of the
University of Pennsylvania is a national leader in cancer
research, patient care, and education. The pre-eminent position
of the Cancer Center is reflected in its continuous designation
as a Comprehensive Cancer Center by the National Cancer Institute
for 30 years, one of 39 such Centers in the United States. The
ACC is dedicated to innovative and compassionate cancer care.
The clinical program, comprised of a dedicated staff of physicians,
nurse practitioners, nurses, social workers, physical therapists,
nutritionists and patient care coordinators, currently sees over
50,000 outpatient visits, 3400 inpatient admissions, and provides
over 24,000 chemotherapy treatments, and more than 65,000 radiation
treatments. Not only is the ACC dedicated to providing state-of-the-art
cancer care, the latest forms of cancer prevention, diagnosis,
and treatment are available to our patients through clinical
themes that developed in the relentless pursuit to eliminate
the pain and suffering from cancer. In addition, the ACC is home
to the 300 research scientists who work relentlessly to determine
the pathogenesis of cancer. Together, the faculty are committed
to improving the prevention, diagnosis and treatment of cancer.
Founded in 1994 by Abramson
Cancer Center specialists with a mission to help cancer
patients, families, health care professionals and the general public
get accurate cancer-related information at no charge, OncoLink is
one of the oldest, largest, and most trusted sources for cancer
information on the Internet.
PENN Medicine is a $2.9 billion enterprise
dedicated to the related missions of medical education, biomedical
research, and high-quality patient care. PENN Medicine consists
of the University of Pennsylvania School of Medicine (founded in
1765 as the nation's first medical school) and the University of
Pennsylvania Health System.
Penn's School of Medicine is ranked #2 in the nation for receipt
of NIH research funds; and ranked #3 in the nation in U.S. News
& World Report's most recent ranking of top research-oriented
medical schools. Supporting 1,400 fulltime faculty and 700 students,
the School of Medicine is recognized worldwide for its superior
education and training of the next generation of physician-scientists
and leaders of academic medicine.
The University of Pennsylvania Health System includes three hospitals,
all of which have received numerous national patient-care honors [Hospital
of the University of Pennsylvania; Pennsylvania Hospital, the nation's
first hospital; and Penn Presbyterian Medical Center]; a faculty practice
plan; a primary-care provider network; two multispecialty satellite
facilities; and home care and hospice.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.